This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Pilot Clinical Trial for Poorly Differentiated Thyroid Cancer - Correlation to Retinoid and Peroxisome-proliferator-activated Receptor (PPARy) Expression

This study has been completed.
American Cancer Society, Inc.
Eisai Inc.
Information provided by (Responsible Party):
University of Colorado, Denver Identifier:
First received: July 17, 2008
Last updated: December 16, 2013
Last verified: December 2013

This study plans to learn more about a drug called bexarotene for the treatment of advanced thyroid cancer. Subjects are asked to be in this study because they have thyroid cancer that will not respond to radioactive iodine therapy and shows signs of aggressive behavior.

Bexarotene has been FDA approved for the treatment of a type of skin cancer called cutaneous T-cell lymphoma, but has not been FDA approved for this use. Bexarotene is investigational in the treatment of thyroid cancer.

The purpose of this research study is to test how well the study drug works in humans. The study doctors want to know if:

  1. The subjects thyroid cancer gets smaller while you are taking the study drug.
  2. The subjects thyroid cancer takes up radioactive iodine better after treatment with the study drug than before treatment.

Condition Intervention Phase
Thyroid Cancer Drug: Bexarotene Early Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Rexinoid Therapy for Poorly Differentiated Thyroid Cancer: A Pilot Clinical Trial and Correlation to Retinoid and PPARy Receptor Expression

Resource links provided by NLM:

Further study details as provided by University of Colorado, Denver:

Primary Outcome Measures:
  • Change in Tumor Size [ Time Frame: 1 year ]
    To assess the tumor response of recurrent or metastatic radioiodine resistant thyroid cancer to bexarotene therapy using standard RECIST criteria

Enrollment: 10
Study Start Date: November 2008
Study Completion Date: February 2013
Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Bexarotene
Open label - all patients receive intervention
Drug: Bexarotene
Bexarotene will be given by mouth once a day every day for 1 year. The dose to be used will be 300 mg/m2.
Other Name: LGD-1069


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject must have a histologically/cytologically confirmed diagnosis of papillary, follicular, or anaplastic thyroid cancer (any follicular cell derived thyroid cancer).
  • Subjects must have evidence of follicular cell-derived thyroid cancer progression. In patients with anatomically stable disease, PET positive lesions will also be eligible given the poor prognostic risk for PET positive thyroid cancer.
  • Subjects must not be eligible for surgical resection.
  • Subjects must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
  • Subjects must have laboratory values that fall within certain ranges.
  • Subjects must be age 18 years or older.
  • Subjects must provide written informed consent prior to any study procedures being performed.
  • Females of childbearing potential must have a negative pregnancy test prior to enrollment.
  • All eligible subjects must be willing to use adequate contraception throughout the duration of the study.
  • Subjects must be willing to submit a primary tumor tissue sample for immunohistochemical analysis.
  • Subjects have the option of providing one additional test tube of blood taken at baseline, 6 months and 1 year for banking of plasma for potential future studies (no genetic testing will be conducted). The current planned analysis is for the assessment of a potential peripheral marker for rexinoid responsive cancer - leukemia inhibitory factor (LIF)

Exclusion Criteria:

  • Subjects with a known history of hyperlipidemia refractory to treatment.
  • Subjects with a known history of hypertriglyceridemia refractory to treatment.
  • Subjects with leukopenia below the reference range for the University of Colorado Hospital (UCH) laboratory.
  • Subjects, who are pregnant, have a desire to become pregnant or are breastfeeding.
  • Subjects who are unwilling or unable to comply with study medication administration, or study guidelines, as determined by the investigator.
  • Subjects with any prior history of malignancy with the exception of adequately treated basal cell skin cancer, in situ cervical cancer or other cancer for which the subject has been disease free for 3 years or more.
  • Subjects without radiographically assessable disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00718770

United States, Colorado
University of Colorado Cancer Center
Aurora, Colorado, United States, 80045
Sponsors and Collaborators
University of Colorado, Denver
American Cancer Society, Inc.
Eisai Inc.
Principal Investigator: Joshua Klopper, MD University of Colorado, Denver
  More Information

Responsible Party: University of Colorado, Denver Identifier: NCT00718770     History of Changes
Other Study ID Numbers:
Study First Received: July 17, 2008
Results First Received: August 2, 2013
Last Updated: December 16, 2013

Keywords provided by University of Colorado, Denver:
Not respond
Radioactive iodine
Shows signs
Aggressive behavior

Additional relevant MeSH terms:
Thyroid Diseases
Thyroid Neoplasms
Endocrine System Diseases
Endocrine Gland Neoplasms
Neoplasms by Site
Head and Neck Neoplasms
Anticarcinogenic Agents
Protective Agents
Physiological Effects of Drugs
Antineoplastic Agents processed this record on June 23, 2017